PeptiDream Inc. FY2026 Q2 Earnings Report

Quick View

Executive Summary

Although revenue continued to increase, the operating loss was not eliminated, resulting in another period in which the delay in monetization persisted. Revenue was ¥9.23B (¥8.54B in the prior year, YoY +8.0%), Operating Income was ¥-2.53B (¥-2.63B in the prior year, YoY +3.5%), and Net Income was ¥-2.00B (¥-2.12B in the prior year, YoY +5.8%). The gross margin improved to 43.0%; however, SG&A expenses increased at a faster pace than revenue growth, limiting the improvement in operating performance.

Factors Affecting Performance

【Revenue】Revenue was ¥9.23B, representing an 8.0% year-on-year increase. Radiopharmaceuticals, which accounted for 87.0% of the revenue mix, grew by 3.1%, while Drug Discovery and Development, which accounted for 13.0%, grew by 57.9%. The growth of the latter segment drove the overall revenue growth rate higher.

【Profitability】Gross profit was ¥3.97B, and the gross margin improved to 43.0% from the equivalent of 37.0% in the prior year. Meanwhile, SG&A expenses increased year on year to ¥3.84B, offsetting the improvement in gross profit. By segment, Operating Income in Radiopharmaceuticals declined by 44.4% year on year to ¥0.24B, with the operating margin falling to 3.0%. Drug Discovery and Development recorded an Operating Loss of ¥2.73B, a 9.4% year-on-year increase in the loss, as upfront investments continued. The Company recorded an Operating Loss of ¥2.53B and a Net Loss of ¥2.00B, resulting in higher revenue but lower earnings.

Segment Analysis

Radiopharmaceuticals generated revenue of ¥8.03B (+3.1%) and accounted for 87.0% of total Company revenue, making it the core business. However, Operating Income declined by 44.4% year on year to ¥0.24B, and the operating margin fell to 3.0%, highlighting the deterioration in profitability. Drug Discovery and Development achieved high growth, with revenue of ¥1.20B (+57.9%), but continued to bear a significant upfront investment burden, recording an Operating Loss of ¥2.73B, equivalent to a margin of -227.5%. The Company-wide Operating Loss of ¥2.53B does not reflect a structure in which the expansion of losses in Drug Discovery and Development exceeds the contraction of profit in Radiopharmaceuticals; however, both segments are commonly facing profitability pressure.

Key Financial Indicators

【Profitability】The Operating Margin was -27.5%, improving from the equivalent of -30.7% in the prior year, while the Net Profit Margin was -21.7%; both remained negative.【Cash Flow Quality】Operating Cash Flow (OCF) was ¥-1.82B, equivalent to 0.91 times the Net Loss of ¥-2.00B. The direction of earnings and cash flow was broadly consistent; however, an increase in inventories (¥-0.49B) and a decrease in trade payables (¥-0.74B) absorbed cash, resulting in negative Free Cash Flow of ¥-2.43B.【Investment Efficiency】ROE was -4.1%. Total assets were ¥72.22B, and the total asset turnover ratio remained low, indicating that capital efficiency continues to languish.【Financial Soundness】The Equity Ratio remained high at 67.2%, and the Company maintained ample liquidity with cash and deposits of ¥23.60B. On the other hand, interest-bearing debt totaled approximately ¥15.69B, including both current and non-current debt, and because operating results are negative, the Company is unable to absorb its interest burden through earnings.

Cash Flow Analysis

Operating Cash Flow was ¥-1.82B, an 83.4% improvement from ¥-10.95B in the prior year, and remained broadly consistent with the Net Loss of ¥-2.00B. Investing Cash Flow was ¥-0.61B, of which capital expenditures accounted for ¥-0.52B, indicating that asset investments related to research and development continue. Financing Cash Flow was ¥-2.71B, with a substantial reduction in short-term borrowings and share repurchases of ¥-1.00B serving as the main sources of cash outflow. Consequently, Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was negative at ¥-2.43B, as headwinds from working capital resulting from increased inventories and decreased trade payables restrained cash generation. Cash and cash equivalents at period-end were ¥23.60B, providing sufficient financial flexibility for the immediate funding outlook.

Earnings Quality

Current-period results were primarily comprised of an Operating Loss of ¥2.53B. The net impact of financial income of ¥0.14B and financial expenses of ¥0.26B was a modest negative factor, and no significant one-off items equivalent to extraordinary gains or losses were identified. Profit Before Tax was ¥-2.66B, and income taxes were ¥-0.66B, resulting in a Net Loss of ¥-2.00B after tax. Comprehensive Income was ¥-2.01B, only slightly different from Net Income attributable to owners of the parent of ¥-2.00B, with no significant divergence attributable to other comprehensive income, such as foreign currency translation adjustments. The fact that Operating Cash Flow of ¥-1.82B was close to the Net Loss of ¥-2.00B indicates that earnings and cash flow remain consistent. However, changes in working capital items such as inventories and trade payables should be monitored, as they may affect future cash-generation capacity.

Earnings Forecast and Guidance

The Full-Year forecast is revenue of ¥32.00B and Operating Income of ¥4.60B. Revenue for the cumulative Q2 period was ¥9.23B, representing a progress rate of 28.8%, below the simple midyear progress benchmark of 50%. While Operating Income was negative at ¥-2.53B in the current quarter, the Company forecasts positive Full-Year Operating Income of ¥4.60B, which presupposes a substantial improvement in profitability during the second half. Both the earnings forecast and the dividend forecast are stated as “None” for revisions, indicating that management is maintaining its initial forecasts at this time. The accumulation of revenue and realization of highly profitable milestone income and other items during the second half will be key to achieving the Full-Year plan.

Shareholder Returns

The dividend forecast is ¥0, and no interim dividend was paid for the current quarter. Given the recognition of a Net Loss, the Payout Ratio is mathematically zero, and the no-dividend policy is consistent with the earnings situation. On the other hand, the Company conducted share repurchases of ¥1.00B, positioning this as a capital policy initiative supported by ample cash and deposits of ¥23.60B. However, as both Operating Cash Flow and Free Cash Flow are negative, it should be noted that this does not represent a return based on the cash-generation capacity of the business itself, but rather a response utilizing existing cash buffers.

Risk Factors

1. Segment Concentration Risk: Radiopharmaceuticals accounts for 87.0% of revenue, while Operating Income in this segment declined by 44.4% year on year and the operating margin fell to 3.0%. This creates a structure in which deterioration in the profitability of the core business directly affects Company-wide performance.

2. Monetization Delay Risk: Drug Discovery and Development achieved revenue growth of +57.9%, while its Operating Loss expanded to ¥2.73B (+9.4% year on year), creating uncertainty regarding the timing of monetization of upfront investments.

3. Cash Flow and Working Capital Risk: Free Cash Flow was ¥-2.43B, with increased inventories (¥-0.49B) and decreased trade payables (¥-0.74B) constraining cash generation. If working capital continues to deteriorate while operating losses persist, the rate of cash consumption could accelerate.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Both the Company’s Operating Margin and Net Profit Margin are negative, and the Company’s relative position within the industry cannot be evaluated because median data is not available.

Growth and Capital Efficiency

Revenue growth remained positive at 8.0%; however, relative evaluation is deferred because industry median data is unavailable.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Although revenue continues to increase, Operating Income in the core Radiopharmaceuticals segment declined by 44.4% year on year, and the operating margin fell to 3.0%. This indicates a structure in which top-line growth alone has not translated directly into improved profitability.

2. Against Full-Year guidance of Operating Income of ¥4.60B, cumulative Q2 results showed a significant divergence, with an Operating Loss of ¥2.53B. The extent to which profitability can improve during the second half will therefore be the key focus going forward.

3. The solid financial foundation, comprising an Equity Ratio of 67.2% and cash and deposits of ¥23.60B, provides a certain degree of resilience despite continuing Operating Losses and negative Free Cash Flow. At the same time, the deterioration in working capital efficiency, particularly involving inventories and trade payables, is structurally constraining cash-generation capacity.

Theoretical Share Price (Reference Value)

Sensitivity: ¥339–¥360 at Cost of Equity ±1%; ¥348–¥350 at ω ±0.1.

Notes:

• Because forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets as of the quarter-end are used (there is a timing difference relative to the Full-Year forecast).

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / These figures are mechanically calculated solely from publicly disclosed data and are not forecasts of market share prices or recommendations for specific investment actions, nor do they predict or guarantee future share prices.)

---

This report is an automatically generated earnings analysis document produced by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

PeptiDream’s FY2026 Q2 performance showed modest top-line growth and narrower losses, but it remains materially behind its full-year profit plan. Revenue increased 8.0% year on year to ¥9.23bn. Gross profit rose to ¥3.97bn from ¥3.17bn, lifting the gross margin to 43.0% from 37.1%, an expansion of approximately 590bp. Reported operating loss narrowed by ¥0.09bn to ¥2.53bn. The operating margin improved by approximately 320bp to -27.5% from -30.7%, but remains substantially below a sustainable profitability level. Net loss attributable to owners narrowed 5.8% to ¥2.00bn, equivalent to diluted EPS of -¥15.51. The annualized DuPont ROE was -8.2%, driven principally by the -21.7% net margin rather than excessive financial leverage. Revenue momentum was positive, and SG&A increased 5.1%, slower than revenue growth, indicating some operating-cost discipline. Nevertheless, the company has not yet converted its improved gross margin into reported operating profitability. Operating cash flow was negative ¥1.82bn and free cash flow was negative ¥2.43bn, reflecting the cash requirements of the business during the first half. Cash outflow from inventories and lower payables offset a sizeable cash inflow from receivables collection. The balance sheet remains well capitalized, with a 67.2% equity ratio and cash and equivalents of ¥23.60bn. Debt structure improved in tenor through a substantial shift from short-term borrowings to long-term borrowings. Goodwill of ¥8.37bn represents 17.2% of equity, a manageable level but one that requires continued validation through the performance of acquired assets. Against FY2026 guidance, first-half revenue progress was 28.8%, well below the normal 50% midpoint benchmark. More importantly, the company must move from a ¥2.53bn first-half operating loss to achieve its ¥4.60bn full-year operating-profit forecast, making second-half execution the central earnings issue. The unchanged guidance indicates management still expects a heavily second-half-weighted outcome, but the current run rate implies a high delivery hurdle.

Profitability Analysis

The annualized three-factor DuPont decomposition produces ROE of -8.2%, comprising a -21.7% net profit margin, 0.255x annualized asset turnover, and 1.49x financial leverage. The dominant negative driver is the net margin, while leverage is moderate and does not appear to be the source of the weak return profile. Annualized asset turnover of 0.255x is low, consistent with a research-led pharmaceutical platform carrying substantial fixed and strategic assets relative to current revenue. Revenue growth of 8.0% and gross-margin expansion to 43.0% are constructive operating developments. Gross-margin expansion of about 590bp suggests improved revenue mix, pricing, or cost absorption, although the disclosed financial data does not quantify the individual drivers. Reported operating loss narrowed to ¥2.53bn and the operating margin improved by about 320bp, but the -27.5% EBIT margin remains the most material operating-efficiency concern. This directly addresses the LOW_OPERATING_EFFICIENCY alert: a negative 27.5% EBIT margin indicates that current revenue and gross profit do not yet absorb the company’s reported operating cost base. SG&A rose 5.1% to ¥3.84bn, below revenue growth, which is favorable operating leverage at the SG&A line. However, earnings recovery remains incomplete because the company is still loss-making at operating and net-income levels. Finance costs of ¥0.26bn exceeded finance income of ¥0.14bn, resulting in a modest net financing burden. The five-factor analysis shows an interest burden of 1.049x, a mathematical consequence of negative EBIT and profit before tax and therefore not an indicator of positive interest coverage. The effective tax rate was 24.8%, with a tax benefit of ¥0.66bn reducing the pre-tax loss of ¥2.66bn to a net loss of ¥2.00bn. ROIC of -5.9% also triggers the CAPITAL_EFFICIENCY alert: negative operating returns indicate that the existing invested capital base, including ¥19.34bn of PPE and ¥8.37bn of goodwill, is not currently generating an adequate operating return. For a drug-discovery business, sustained improvement depends on scaling partnership, milestone, and commercialization-related revenue faster than the underlying research and platform cost base.

Growth Assessment

First-half revenue growth of 8.0% to ¥9.23bn demonstrates continued commercial and partnership activity, while the 43.0% gross margin indicates better gross-profit conversion than the prior period. Revenue is nevertheless only 28.8% of the ¥32.00bn full-year forecast, versus a standard 50% first-half progress rate. The deviation is 21.2 percentage points below the standard midpoint and therefore materially exceeds the 10-percentage-point flag threshold. Operating performance is further behind plan: the company recorded a ¥2.53bn first-half operating loss versus full-year guidance for ¥4.60bn operating profit. Net income was a ¥2.00bn loss versus a ¥3.00bn full-year profit target. Accordingly, the second half must deliver approximately ¥22.77bn of revenue, ¥7.13bn of operating-profit improvement versus the reported first-half loss, and ¥5.00bn of net-income improvement to meet guidance. This outcome requires significant second-half revenue recognition and/or milestones, licensing income, commercialization contributions, and cost absorption relative to the first-half run rate. Management has not revised either earnings or dividend forecasts. The unchanged forecast preserves the possibility of a back-end-loaded result, but it raises the sensitivity of the full-year outcome to the timing and realization of major business-development events. For a pharmaceutical discovery company, revenue sustainability is inherently linked to counterparty decisions, development milestones, regulatory progress, and the conversion of its peptide-discovery platform into recurring economics. The current revenue growth and gross-margin expansion are positive, but profitability guidance requires evidence of a substantially stronger second half.

Financial Health

Financial health is supported by a strong equity base, substantial cash holdings, and moderate reported leverage. Total equity was ¥48.56bn, equal to a 67.2% equity ratio, while total liabilities were ¥23.67bn. Interest-bearing debt was ¥15.69bn, producing a conservative debt-to-equity ratio of 0.49x and debt-to-capital of 24.4%, both within investment-grade-style benchmark ranges. Current assets of ¥33.07bn and estimated current liabilities of ¥7.97bn imply a current ratio of approximately 4.15x. Excluding inventories, the estimated quick ratio is approximately 3.69x. Cash and equivalents of ¥23.60bn covered short-term loans of ¥2.61bn by approximately 9.0x. Therefore, the LIQUIDITY_STRESS alert stating cash-to-short-term-debt of 0.00x is not supported by the supplied balance-sheet figures; liquidity coverage appears strong on the reported balances. There is no maturity mismatch evident from current assets relative to estimated current liabilities. Short-term loans declined by ¥14.43bn, or 84.7% year on year, to ¥2.61bn. At the same time, long-term loans increased by ¥11.76bn to ¥13.08bn, indicating a refinancing or maturity-extension shift from short-term to long-term funding. This reduces near-term refinancing pressure, although it increases the importance of maintaining sufficient future cash generation to service the longer-dated debt. Finance costs of ¥0.26bn are modest in absolute terms but remain relevant while operating income is negative. Goodwill was ¥8.37bn, or 11.6% of assets and 17.2% of equity, below the framework’s elevated-risk threshold; this limits balance-sheet dependence on acquisition value retention. Deferred tax assets were ¥7.29bn, equivalent to 15.0% of equity, and their recoverability remains linked to the realization of future taxable profitability.

Notable B/S Changes

Short-term loans: -¥14.43bn (-84.7%) to ¥2.61bn - substantial reduction in near-term debt and improved refinancing-risk profile. Long-term loans: +¥11.76bn to ¥13.08bn - indicates a major shift toward longer-term funding; near-term liquidity improves, while future debt-service capacity depends on operating-cash-flow recovery. Treasury stock: -¥0.82bn (-43.1%) to -¥2.72bn - reflects continued share repurchases, including ¥1.00bn during the first half, and reduces equity and cash flexibility. Accounts receivable: -¥1.61bn (-23.4%) to ¥4.50bn - collection generated ¥1.37bn of operating cash flow during the period, although DSO remains elevated at 89 days. Cash and cash equivalents: -¥5.08bn (-17.7%) to ¥23.60bn - reflects negative operating and investing cash flow as well as financing outflows, but the remaining cash balance remains substantial. Deferred tax assets: +¥0.71bn (+10.9%) to ¥7.29bn - a sizeable asset relative to equity whose value depends on future taxable-profit generation.

Cash Flow Quality

Operating cash flow was negative ¥1.82bn, broadly in line with the ¥2.00bn net loss. The reported OCF-to-net-income ratio was 0.91x; because both operating cash flow and net income were negative, this ratio should be interpreted cautiously, but it does not indicate that cash outflow was materially worse than the accounting loss. The ratio is above the 0.8x quality-warning threshold, while the -0.2% accruals ratio is also not indicative of elevated accrual risk. Cash conversion remains weak in absolute terms because the business is consuming cash rather than producing it. Inventory increased by ¥0.49bn, creating an operating-cash outflow, and the HIGH_INVENTORY_DAYS alerts should be treated as material: DIO of 128 days exceeds both the 90-day and 60-day thresholds. Elevated inventory days can indicate slower inventory conversion, production ahead of demand, or a working-capital build that will need to be monetized through future sales. Receivables declined, contributing a ¥1.37bn operating-cash inflow, but the HIGH_RECEIVABLE_DAYS alert also requires monitoring: DSO of 89 days exceeds the 60-day threshold and indicates relatively slow collections relative to revenue. The decline in receivables during the period is favorable, but the ending receivables balance of ¥4.50bn and high DSO mean collection timing remains relevant to liquidity and revenue quality. Payables decreased by ¥0.74bn, producing a cash outflow and indicating that operating cash flow was not being supported by extended supplier financing. Capital expenditures were ¥0.52bn and intangible-asset purchases were ¥0.12bn. Free cash flow was negative ¥2.43bn, so internally generated cash did not cover operating requirements and investment spending in the first half. Financing activities consumed ¥2.71bn, including ¥9.98bn of share repurchases, while the refinancing activity shifted debt maturity toward long-term borrowings. Cash and equivalents decreased by ¥5.08bn to ¥23.60bn, which remains ample but should be monitored if negative FCF persists.

Dividend Sustainability

The company reported Q2 DPS of ¥0 and forecasts full-year DPS of ¥0. Accordingly, there is no cash-dividend payout ratio or dividend-funded liquidity burden in FY2026 based on the disclosed policy. Dividend sustainability is therefore not the immediate capital-allocation issue. The more relevant shareholder-return measure is the total return ratio because the company repurchased ¥1.00bn of shares during the first half. As the company recorded a net loss and negative free cash flow, a meaningful earnings-based total return ratio cannot be calculated, and the repurchase was funded from balance-sheet liquidity rather than contemporaneous earnings or FCF. Treasury stock increased by ¥0.82bn, or 43.1%, to ¥2.72bn, consistent with continued buyback activity. The buyback amount is modest relative to ¥23.60bn of cash and ¥48.56bn of equity, but it reduces financial flexibility while operating cash flow remains negative. The absence of dividends preserves cash for research, operations, debt service, and potential strategic investment. Future shareholder distributions should remain contingent on sustainable operating cash generation and progress toward the full-year profitability plan.

Risk Assessment

Business risks include Second-half execution risk is high: first-half revenue represents only 28.8% of the ¥32.00bn full-year target, and the company must reverse a ¥2.53bn first-half operating loss to meet ¥4.60bn full-year operating-profit guidance., Pharmaceutical development and partnership risk is material because discovery-platform economics can depend on milestone timing, clinical progress, partner prioritization, regulatory outcomes, and the successful commercialization of partnered assets., Operating-efficiency risk remains high: the -27.5% EBIT margin and -5.9% ROIC show that the current asset and operating-cost base is not yet generating adequate returns., Working-capital risk is elevated: DSO of 89 days and DIO of 128 days may delay cash conversion and can signal slower collection or inventory monetization., Goodwill impairment risk is present, although currently moderated by goodwill equal to 17.2% of equity; future underperformance of acquired operations or assets could require reassessment..

Financial risks include Negative operating cash flow of ¥1.82bn and negative free cash flow of ¥2.43bn create a risk of continued cash burn if profitability recovery is delayed., Long-term loans increased to ¥13.08bn as debt was refinanced away from short-term borrowings; this improves maturity management but leaves the company dependent on future cash generation for debt servicing., Finance costs of ¥0.26bn exceed finance income while EBIT is negative, limiting financial flexibility until operating profitability improves., Share repurchases of ¥1.00bn reduce cash reserves during a period of negative free cash flow..

Key concerns include The highest-priority issue is the scale of second-half earnings required to support unchanged FY2026 guidance., The next key concern is whether gross-margin improvement can translate into positive operating income rather than remaining offset by the reported operating cost base., Cash conversion should be monitored through receivable days, inventory days, operating cash flow, and the pace of cash-balance decline., For an innovator pharmaceutical company, clinical, regulatory, and partner-decision risk can cause significant volatility in milestone-driven revenue and earnings..

Investment Implications

Key takeaways include Revenue growth of 8.0%, gross-margin expansion of approximately 590bp, and a narrower net loss show incremental operating improvement., Reported profitability remains weak, with operating margin of -27.5%, annualized ROE of -8.2%, and ROIC of -5.9%., The balance sheet is comparatively resilient, with a 67.2% equity ratio, approximately 4.15x current ratio, and cash covering short-term loans by about 9.0x., Debt maturity has been materially improved through a reduction in short-term borrowings and an increase in long-term borrowings., The unchanged full-year forecast requires an exceptionally strong second half, making execution against revenue recognition and profitability milestones decisive..

Metrics to watch include Quarterly revenue progress toward the ¥32.00bn FY2026 forecast, Operating-income trajectory toward the ¥4.60bn FY2026 forecast, Gross margin and reported operating margin, Operating cash flow, free cash flow, and cash and equivalents, DSO of 89 days and DIO of 128 days, Long-term debt, finance costs, and debt-service capacity, Goodwill carrying value and evidence supporting impairment-test assumptions.

Regarding relative positioning, PeptiDream combines a stronger-than-average liquidity and equity cushion with a currently weak earnings and capital-efficiency profile. Its balance-sheet risk appears contained relative to highly leveraged growth companies, but its relative operating position depends on converting platform, partnership, and pharmaceutical-development activity into sufficiently large and recurring high-margin revenue to close the substantial second-half guidance gap.